GLUCOPHAGE XR^®
(metformin hydrochloride)
MERCK
HK Reg. No. HK-68753 (14 Jul, 2025)
Composition:²

• One prolonged release tablet contains 500 mg metformin hydrochloride corresponding to 390 mg metformin base

Indication:²

• Reduction in the risk or delay of the onset of type 2 diabetes mellitus in adult, overweight patients with impaired glucose tolerance (IGT) and/or impaired fasting glucose (IFG), and/or increased HbA1C who are:

✓ at high risk for developing overt type 2 diabetes mellitus and

✓ still progressing towards type 2 diabetes mellitus despite implementation of intensive lifestyle change for 3 to 6 months

• Treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycemic control. Glucophage XR may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin

• Polycystic ovary syndrome (PCOS)

References

2. EMC. Glucophage SR 500 mg prolonged release tablets Healthcare Professionals (SmPC). 31 Mar 2025. Available from: https://www.medicines.org.uk/emc/product/6298/smpc. [Accessed 18 July 2025].